Oliceridine in the Prevention of Catheter-Related Bladder Discomfort: A Single-Center, Randomized, Double-Blind, Prospective Trial.

PURPOSE: To investigate whether oliceridine is more effective than morphine in reducing the incidence of moderate-to-severe catheter-related bladder discomfort (CRBD) in male patients after transurethral surgery.

PATIENTS AND

METHODS

This prospective, randomized, double-blind trial enrolled 372 adult male patients undergoing elective transurethral surgery with urinary catheterization. Patients were randomized to receive oliceridine (1 mg) or morphine (2 mg) intravenously 5 minutes before surgery end. CRBD incidence/severity, Numerical Rating Scale. (NRS), Postoperative nausea and vomiting (PONV), Aldrete recovery scores, adverse events, and the Quality of Recovery-15 scale (QoR-15) score were assessed.

RESULTS

The incidence and severity of CRBD at 3 hours postoperatively were significantly lower in the oliceridine group than in the control group (21.5% vs 72.1%; RR 0.298, 95% CI: 0.220-0.403; P<0.001). QoR-15 scores were higher in the oliceridine group on postoperative days 1-3 (P≤0.005). No serious adverse events occurred, and nausea/vomiting incidence and pain score showed no significant difference.

CONCLUSION

Intraoperative oliceridine (1 mg) effectively reduces moderate-to-severe CRBD incidence and severity, improves early postoperative recovery quality, and is well-tolerated in male transurethral surgery patients.